跳转至内容
Merck
CN

AB9604

Anti-Semaphorin 3A Antibody, central region

Chemicon®, from rabbit

登录 查看组织和合同定价。

选择尺寸

关于此项目

UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Conjugate:
unconjugated
Clone:
polyclonal
Application:
WB
Citations:
2

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

biological source

rabbit

conjugate

unconjugated

antibody form

affinity purified immunoglobulin

antibody product type

primary antibodies

clone

polyclonal

purified by

affinity chromatography

species reactivity

human, rat

manufacturer/tradename

Chemicon®

technique(s)

western blot: suitable

NCBI accession no.

NM_006080.2

UniProt accession no.

Q14563

shipped in

dry ice

target post-translational modification

unmodified

Quality Level

100

Gene Information

human ... SEMA3A(10371)

Immunogen

Synthetic peptide from the central region of human semaphorin 3A.

Application

Anti-Semaphorin 3A Antibody, central region detects level of Semaphorin 3A & has been published & validated for use in WB.
Western blot: 1:1,000 on neonatal rat brain and recombinant human Semaphorin 3A/Fc chimera (95/125 kDa). The antibody reacts with the ~95 kDa protein. The suggested antibody diluent is PBS containing 5% non-fat milk and 0.04% Tween 20.

Optimal working dilutions must be determined by the end user.

Biochem/physiol Actions

It is expected that the antibody will also react with mouse.
Semaphorin 3A. The immunogen sequence has low homology with other semaphorin family members.

Physical form

Liquid in PBS containing 50% glycerol, 1 mg/mL BSA and 0.05% sodium azide.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

未找到合适的产品？  

试试我们的产品选型工具.

存储类别

10 - Combustible liquids

wgk

WGK 2

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Transmembrane proteoglycans syndecan-2, 4, receptor candidates for the impact of HGF and FGF2 on semaphorin 3A expression in early-differentiated myoblasts.
Do, MK; Shimizu, N; Suzuki, T; Ohtsubo, H; Mizunoya, W; Nakamura, M; Sawano, S; Furuse et al.
Physiological Reports null
Haynes Shek Hei Yuan et al.
Oncotarget, 9(32), 22618-22630 (2018-06-02)
One hallmark of cancer is its ability to recruit a vascular supply to support rapid growth. Suppression of angiogenesis holds potential as a second-line or adjuvant therapy to stunt cancer growth, progression, metastasis, and post-resection regeneration. To begin to test

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持